Trial Profile

A Phase 1 Trial of TGN-S11 in Patients With Human Papillomavirus (HPV)-Associated Relapsed, Resistant or Metastatic Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 22 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pembrolizumab (Primary) ; TGN-S11 (Primary)
Indications Human papillomavirus infections; Squamous cell cancer
Focus Adverse reactions
Sponsors Toragen

Most Recent Events

18 Nov 2024 According to Toragen media release, the study is ongoing with patients currently being dosed in Part 1 Cohort 4 and Part 2 Level 2. study completion expected by the end of 2024.
18 Nov 2024 Results presented in the Toragen Media Release
09 Aug 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Oct 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com